FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. (Q37292055)
Jump to navigation
Jump to search
scientific article published on 10 October 2008
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. |
scientific article published on 10 October 2008 |
Statements
1 reference
FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. (English)
1 reference
Qin Ryan
1 reference
Amna Ibrahim
1 reference
Martin H Cohen
1 reference
John Johnson
1 reference
Chia-wen Ko
1 reference
Rajeshwari Sridhara
1 reference
Robert Justice
1 reference
Richard Pazdur
1 reference
10 October 2008
1 reference
Identifiers
1 reference